Two children developed papillary thyroid carcinoma after allogeneic bone marrow transplantation (BMT) probably due to radiotherapy during remission and pretransplantation conditioning. Establishing a relationship between the cellular thyroid stimulating hormone (TSH) effect and development of carcinoma in cases with high serum TSH concentrations is difficult. After BMT, patients should be regularly followed up with thyroid ultrasound and, when nodularity is found, fine needle aspiration and/or open biopsy are recommended.
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(Arch Dis Child 1994; 71: [256] [257] [258] Papillary thyroid carcinoma can occur at any age and is seen more frequently in children and adolescents than other thyroid malignancies. High thyroid cancer incidence has been reported in survivors of atomic bombing. Young patients with papillary thyroid carcinoma generally have a history of radiotherapy for thymic enlargement, cervical lymphadenopathy, or Hodgkin's lymphomas.1 2 Patients undergoing bone marrow transplantation (BMT) for haematological malignancies have proved to be at risk for second tumours. 3 4 Although 'thyroid carcinomas have rarely been described,5 our experience shows this could be a malignant 'late effect' after BMT.
Case reports (see ALL patients who have received irradiation treatment have an increased risk of second neoplasms particularly in the central nervous system.6 In 9720 patients, 43 second tumours were reported. All 23 patients with central nervous system tumours had cranial irradiation. Furthermore, 32 of the 43 second neoplasms appeared in previously irradiated fields. No data have been reported concerning the three patients who developed thyroid cancer. The first of the two patients we report received irradiation twice (24 Gy cranial irradiation during first line treatment and 10 Gy of fTBI before BMT as part of conditioning regimen). The second received only fTBI three years before diagnosis of thyroid carcinoma. Irradiation fields involved the thyroid region in both patients. The period between irradiation and diagnosis is different in the two patients but is much shorter than the 25-30 year latency period usually observed in patients developing thyroid cancer after irradiation exposure for reasons other than cancer. In following up long term survivors after BMT, care must be taken to exclude the presence of a thyroid tumour, especially when TBI was used during pretransplant conditioning.
Up to 40% of patients exposed to cervical irradiation in doses of 40-50 Gy, as treatment for Hodgkin's disease or cranial tumours,2 had some degree of thyroid dysfunction. Compensated, subclinical hypothyroidism (high TSH with normal thyroxine concentrations) has also been reported after BMT with varying incidence. The hypothesis that high serum TSH concentrations constitute the trigger for the induction of thyroid tumour cells through a growth effect on thyrocytes cannot be excluded.
Thyroid dysfunction, with raised TSH due to primary hypothyroidism, was observed six and two years respectively after TBI in our cases. Ultrasound examination revealed multinodular goitre ( 
